New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
08:39 EDTCMRXChimerix shares remain undervalued, says Cowen
Cowen believes shares of Chimerix remain undervalued following its dinner management. The firm remains confident its SUPPRESS trial for brincidofovir will succeed in 2015 and expects other opportunities for the drug to materialize in 2014. Shares are Outperform rated with a $27 price target.
News For CMRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
06:35 EDTCMRXChimerix price target raised to $63 from $44 at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer raised his price target for Chimerix to $63 on expectations the company will gain approval next year for three antiviral indications simultaneously. All evidence points to a high probability of success for the Phase 3 study of brincidofovir for allogeneic hematopoetic stem cell transplant, Schimmer tells investors in a research note. Shares have rallied as key data readouts near for brincidofovir, he notes. The analyst keeps an Overweight rating on Chimerix.
August 3, 2015
08:11 EDTCMRXChimerix completes enrollment for Brincidofovir Phase 3 AdVise trial
Chimerix announced completion of enrollment of the targeted 200 patients in the Phase 3 AdVise trial evaluating brincidofovir for the treatment of adenovirus infection in immunocompromised patients. Adenovirus is a common virus that leads to upper respiratory or gastrointestinal infections in individuals with a healthy immune system, but it can be rapidly fatal in individuals with a weakened immune system, particularly those who have recently undergone a hematopoietic cell transplant, or bone marrow transplant. There is no approved antiviral treatment for adenovirus infection.
July 23, 2015
08:20 EDTCMRXChimerix announces topline results from animal model for smallpox study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use